GlaxoSmithKline Tagged Articles
GSK agrees to pay $750 million to settle false-claims lawsuit
Brittan’s largest drug maker, GlaxoSmithKline (GSK), has agreed to pay $750 million to settle lawsuits that claim the company knowingly sold substandard baby ointment and other drugs that were manufactured in a plant in Puerto Rico. The false-claims lawsuit was
FDA puts tight restrictions on Avandia due to heart attack, stroke risk
The Food and Drug Administration (FDA) voted today not to remove the Type 2 diabetes drug Avandia from the market, despite studies that indicate the medication puts users at an elevated risk for cardiovascular events, such as heart attack and
FDA warns public to check for stolen Advair inhalers
Consumers and pharmacists who use Advair Diskus inhalers (fluticasone propionate and salmeterol inhalation powder) to treat pulmonary conditions such as asthma and chronic obstructive pulmonary disease (COPD) should check their inhalers because they may be part of stolen lots of inhalers
Dark cloud hangs over Avandia despite FDA vote to keep it on market
After two days of deliberation, a Food and Drug Administration (FDA) advisory panel voted Wednesday to keep the diabetes drug Avandia on the market despite studies that suggest the medication puts people at greater risk of heart attacks and strokes.
GSK to pay $460 million to settle Avandia lawsuits
While an expert panel in the U.S. reviews evidence to decide whether to pull the popular diabetes drug Avandia off the market due to an increased risk of cardiovascular events, BusinessWeek reports that the drug’s maker, GlaxoSmithKline (GSK), has agreed
Increase in availability of generic drugs may raise safety concerns
The new health care reform bill gives senior citizens a rebate to purchase prescription medications; however, increasing availability of drugs for seniors may cause safety concerns, especially when it comes to generic versions of medication, according to a Huffington Post
FDA announces it will review studies linking Avandia to heart attacks
It’s a long time coming. This week the Food and Drug Administration (FDA) announced it is reviewing the primary data from a large, long-term clinical study, known as RECORD, on possible cardiovascular risks associated with the diabetes drug Avandia (rosiglitazone).
Senators ask why dangerous Avandia was not pulled from market
Two U.S. senators are asking the Food and Drug Administration (FDA) why the diabetes drug Avandia is still on the market after an agency oversight board in 2008 urged the agency to remove the GlaxoSmithKline (GSK) drug from the market
Flu patient dies after receiving Relenza inappropriately
The death of a patient suffering from influenza who was treated with Relenza (zanamivir) Inhalation Powder in a manner not approved by the Food and Drug Administration (FDA), has spurred a notification from the drug maker to infectious disease health
